Literature DB >> 27439571

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.

Priya Sriskandarajah1,2, Charlotte Pawlyn1,2, Kabir Mohammed1, Claire E Dearden1, Faith E Davies1,3, Gareth J Morgan1,3, Kevin D Boyd1, Martin F Kaiser1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27439571     DOI： 10.1080/10428194.2016.1198957

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

Review 1.  Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.

Authors:  Luca Bertamini; Giuseppe Bertuglia; Stefania Oliva
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

2.  Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Authors:  Yayoi Matsumura-Kimoto; Junya Kuroda; Hitomi Kaneko; Yuri Kamitsuji; Shin-Ichi Fuchida; Aya Nakaya; Hirohiko Shibayama; Nobuhiko Uoshima; Isao Yokota; Hitoji Uchiyama; Hideo Yagi; Satoru Kosugi; Toshimitsu Matsui; Jun Ishikawa; Mitsuhiro Matsuda; Kensuke Ohta; Masato Iida; Hirokazu Tanaka; Masayuki Kobayashi; Katsuya Wada; Chihiro Shimazaki; Shosaku Nomura; Kazunori Imada; Masayuki Hino; Itaru Matsumura; Yuzuru Kanakura; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

3.  Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Authors:  Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff
Journal:  Eur J Haematol       Date:  2021-11-15       Impact factor: 3.674

Review 4.  Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

Authors:  Rafael Ríos-Tamayo; Agustín Martín-García; Carolina Alarcón-Payer; Dolores Sánchez-Rodríguez; Ana María Del Valle Díaz de la Guardia; Carlos Gustavo García Collado; Alberto Jiménez Morales; Manuel Jurado Chacón; José Cabeza Barrera
Journal:  Drug Des Devel Ther       Date:  2017-08-22       Impact factor: 4.162

5.  Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Authors:  Marina Silvia Parisi; Salvatore Leotta; Alessandra Romano; Vittorio Del Fabro; Enrica Antonia Martino; Valeria Calafiore; Rachele Giubbolini; Uros Markovic; Valerio Leotta; Mary Ann Di Giorgio; Daniele Tibullo; Francesco Di Raimondo; Concetta Conticello
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.